Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BIBW 2992 Cause Malignant neoplasm progression? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Malignant neoplasm progression have been filed in association with BIBW 2992. This represents 12.0% of all adverse event reports for BIBW 2992.

6
Reports of Malignant neoplasm progression with BIBW 2992
12.0%
of all BIBW 2992 reports
6
Deaths
4
Hospitalizations

How Dangerous Is Malignant neoplasm progression From BIBW 2992?

Of the 6 reports, 6 (100.0%) resulted in death, 4 (66.7%) required hospitalization.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BIBW 2992. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does BIBW 2992 Cause?

Diarrhoea (16) Nausea (8) Vomiting (8) Renal failure acute (7) Asthenia (5) Decreased appetite (5) Rash (5)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Related Pages

BIBW 2992 Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression BIBW 2992 Demographics